Additional resource needs for viral hepatitis elimination through universal health coverage : projections in 67 low-income and middle-income countries, 2016–30 by Tordrup, D. et al.
www.thelancet.com/lancetgh   Vol 7   September 2019 e1180
Articles
Lancet Glob Health 2019; 
7: e1180–88
Published Online 
July 25, 2019 
http://dx.doi.org/10.1016/
S2214-109X(19)30272-4
See Comment page e1148
WHO Collaborating Centre for 
Pharmaceutical Policy and 
Regulation, University of 
Utrecht, Utrecht, Netherlands 
(D Tordrup MSc); Department of 
HIV and Global Hepatitis 
Programme, and Department 
of Health Systems Governance 
and Financing, WHO, Geneva, 
Switzerland (D Tordrup, 
Y Hutin MD, K Stenberg MSc, 
J A Lauer PhD, M Bulterys MD, 
A Ball MD, G Hirnschall MD); 
School of Public Health, 
University of Michigan, 
Ann Arbor, MI, USA 
(D W Hutton PhD); School of 
Medicine, Stanford University, 
Palo Alto, CA, USA (M Toy PhD); 
and Burnet Institute, 
Melbourne, VIC, Australia 
(N Scott PhD)
Correspondence to: 
Dr Yvan Hutin, Global Hepatitis 
Programme, WHO, Geneva 1211, 
Switzerland 
hutiny@who.int
Additional resource needs for viral hepatitis elimination 
through universal health coverage: projections in 
67 low-income and middle-income countries, 2016–30
David Tordrup, Yvan Hutin, Karin Stenberg, Jeremy A Lauer, David W Hutton, Mehlika Toy, Nick Scott, Marc Bulterys, Andrew Ball, 
Gottfried Hirnschall
Summary
Background The World Health Assembly calls for elimination of viral hepatitis as a public health threat by 2030 
(ie, –90% incidence and –65% mortality). However, WHO’s 2017 cost projections to achieve health-related Sustainable 
Development Goals did not include the resources needed for hepatitis testing and treatment. We aimed to estimate 
the incremental commodity cost of adding scaled up interventions for testing and treatment of hepatitis to WHO’s 
investment scenarios. 
Methods We added modelled costs for implementing WHO recommended hepatitis testing and treatment to the 2017 
WHO cost projections. We quantified additional requirements for diagnostic tests, medicines, health workers’ time, 
and programme support across 67 low-income and middle-income countries, from 2016–30. A progress scenario 
scaled up interventions and a more ambitious scenario was modelled to reach elimination by 2030. We used 2018 best 
available prices of diagnostics and generic medicines. We estimated total costs and the additional investment needed 
over the projection of the 2016 baseline cost.
Findings The 67 countries considered included 230 million people living with hepatitis B virus (HBV) and 52 million 
people living with hepatitis C virus (HCV; 90% and 73% of the world’s total, respectively). Under the progress 
scenario, 3250 million people (2400 million for HBV and 850 million for HCV) would be tested and 58·2 million 
people (24·1 million for HBV and 34·1 million for HCV) would be treated (total additional cost US$ 27·1 billion). 
Under the ambitious scenario, 11 631 million people (5502 million for HBV and 6129 million for HCV) would be 
tested and 93·8 million people (32·2 million for HBV and 61·6 million for HCV) would be treated (total additional 
cost $58·7 billion), averting 4·5 million premature deaths and leading to a gain of 51·5 million healthy life-years by 
2030. However, if affordable HCV medicines remained inaccessible in 13 countries where medicine patents are 
protected, the additional cost of the ambitious scenario would increase to $118 billion. Hepatitis elimination would 
account for a 1·5% increase to the WHO ambitious health-care strengthening scenario costs, avert an additional 
4·6% premature deaths, and add an additional 9·6% healthy life-years from 2016–30.
Interpretation Access to affordable medicines in all countries will be key to reach hepatitis elimination. This study 
suggests that elimination is feasible in the context of universal health coverage. It points to commodities as key 
determinants for the overall price tag and to options for cost reduction strategies. 
Funding WHO, United States Centers for Disease Control and Prevention, Unitaid.
Copyright © 2019 World Health Organization; licensee Elsevier. This is an Open Access article published under the 
CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any 
specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved 
along with the article’s original URL.
Introduction
In 2015, viral hepatitis led to 1·34 million deaths 
globally.1 Most viral hepatitis deaths are secondary to 
cirrhosis and hepatocellular carcinoma, which can 
be prevented with testing and treatment. In 2016, 
the World Health Assembly adopted elimination of 
viral hepatitis as a public health threat by 2030 
(–90% incidence, –65% mor tality).2 Modelling work 
indicated that elimi nation could be achieved by 
reaching sufficient coverage for five core interventions.3,4 
These WHO recom mended interventions are infant 
immunisation against hepatitis B,5 prevention of 
mother-to-child transmission of hepatitis B virus (HBV) 
through timely hepatitis B birth dose vaccination 
and other approaches,5 blood6 and injection safety,7 
harm reduction for people who inject drugs,8 and HBV 
and hepatitis C virus (HCV) testing9 and treatment.10,11 
In 2016, preliminary cost estimates of viral hepatitis 
elimination were done by use of a programme-centred 
approach.4 However, not all countries had been included 
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and the estimates were made before WHO-validated 
baseline estimates, which were generated later in 2017.1
The concept of universal health coverage (UHC)12 
provides the logical framework to scale up these five core 
interventions. In 2017, WHO estimated that to advance 
towards the health targets of the Sustainable Development 
Goals (SDGs), low-income and middle-income countries 
would need to invest an additional US$3944 billion from 
2016 to 2030 for an ambitious scenario, whereas a more 
modest progress scenario would require an additional 
$2929 billion.13 The WHO SDG analysis addressed viral 
hepatitis prevention but did not include testing and 
treatment. WHO recommends treatment of people 
diagnosed with HBV10 and HCV infection.11 HBV 
treatment is indicated only for eligible people and it is 
usually lifelong.10 Short courses of HCV treatment with 
direct acting antivirals lead to cure in more than 90% of 
patients.11 Treatment can be highly cost-effective or cost-
saving from a health-care perspective.14–16 For testing in all 
settings, WHO recommends focused testing in people 
with signs and symptoms of chronic liver disease and 
groups with high HBV or HCV infection prevalence. 
However, if the prevalence of infection in the general 
population exceeds 2–5%, WHO recommends general 
population testing.9,17,18
Progress towards elimination has been modest. 
Prevention is on track, apart from timely birth dose 
vaccination in Africa and harm reduction for people who 
inject drugs.1,19 However, the coverage of testing and 
treatment remains low.20,21 To make the case for scaling 
up, the argument of affordability needs to complement 
the argument of cost-effectiveness. Therefore, we aimed 
to estimate the incremental commodity cost of adding 
scaled up interventions for testing and treatment of 
hepatitis to the progress and ambitious scenarios of 
WHO’s SDG investment scenarios.13
Methods
Scenarios considered
We extended the methods used for WHO’s SDG 
investment model, in the same 67 countries (appendix 
p 7) to add testing and treatment for HBV and HCV 
infection.13 A first flatline scenario consisted of the 
conti nuation of the current testing and treatment 
approaches until 2030. A second progress scenario 
consisted of an increase of testing and treatment 
coverage following the WHO guidelines.9–11 The third 
ambitious elimination scenario consisted of a scaling 
up that would reach the coverage required to achieve 
HBV and HCV elimination.2
General approach
For each of the scenarios, we calculated total commodities 
cost on the basis of unit price and quantities required. We 
quantified staffing needs on the basis of inter ventions 
required and ensured that these needs fit within the 
overall requirements that had been already costed.13 
Finally, we added programme support costs to address 
training, supervision, monitoring, and evaluation. None 
of the costs were discounted.
Interventions
We focused on testing and treatment because prevention 
had been included in the SDG investment model. 
Hepatitis B immunisation, including timely birth dose, is 
included in the Global Vaccine Action Plan.22 Modelling 
studies suggest that this plan should be sufficient to reach 
a substantial component of the HBV incidence reduction 
Research in context
Evidence before this study
In 2016, the World Health Assembly adopted the Global Health 
Sector Strategy for hepatitis that called for its elimination by 
2030. To guide this resolution, WHO had commissioned an 
initial modelling study. However, this projection was done 
before WHO estimated the baseline for service coverage and did 
not use a universal health coverage perspective. In 2017, WHO 
costed the scaling up of universal health coverage to reach the 
health-related Sustainable Development Goals. However, it 
could not include hepatitis because the baseline indicators had 
not yet been established. Studies identified through a MEDLINE 
search using the search terms “hepatitis” and “elimination” and 
“(costing or financing)” for 2015–17 only identified country 
specific costing studies (eg, South Africa, Morocco, Thailand, 
and Australia).
Added value of this study
This work estimated the cost of scaling up interventions for 
the testing and treatment of hepatitis from the baseline to 
the elimination goals, within the perspective of universal 
health coverage and in the context of the Sustainable 
Development Goals. The results of the analysis suggest that 
hepatitis elimination is a high-impact intervention. 
The initiative would require an additional investment of 1·5%, 
but the effect would be proportionally higher, leading to a 
reduction of about 5% in mortality and an increase of about 
10% in healthy life-years.
Implications of all the available evidence
The results of the analysis provide a quantified estimate of the 
resources needed for elimination of hepatitis by 2030 (in 
relation to the expected health impact), which can guide 
national and international stakeholders who have to make 
decisions in terms of financing. Overall, it suggests that 
elimination is feasible in the context of universal health 
coverage. It points to commodities as key determinants for the 
overall price tag and to options for cost reduction strategies.
See Online for appendix
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of the hepatitis elimination strategy.23 The programmatic 
infrastructure of prevention of mother-to-child trans-
mission of HIV and syphilis would provide additional 
opportunities to direct treatments to eligible pregnant 
women, which would further reduce incidence of HBV 
infection.24 The overall health system strengthening 
would improve infection control, including blood and 
injection safety. Harm reduction for people who inject 
drugs is included under HIV prevention.25
Evolution of the HBV and HCV epidemic in the population
For each of the 67 countries, we extrapolated population 
size estimates using the Spectrum tool,26 taking into 
account the mortality effect of the UHC scenarios.13 We 
started with the 2015 prevalence of HBV and HCV 
infection, and adjusted future prevalence accounting for 
new infections per yearly incidence rates, mortality, and 
cures in the case of HCV infection (appendix p 9). We 
then moved individuals from the status of infected to 
tested, diagnosed, and started on treatment to project the 
quantity of resources needed. The annual recalculation 
of the prevalence of infection ensured that the resources 
needed for testing and treatment took into account 
incidence in the case of HCV infection. We assumed the 
incidence of HCV to be stable for the flatline (and equal 
to the estimates for each WHO Region in 2015),1 or 
decreasing to reach –50% for the progress scenario or 
–90% for the ambitious scenario, by 2030, because of the 
prevention interventions. For HBV, we did not consider 
that new chronic infections would be added among 
adults (appendix p 3).
Unit cost for resources needed
We reported all costs in US dollars (2018). We used 2018 
prices for commodity costs, whereas programme costs 
were inflated from US dollars in 2010 using country-
specific gross domestic product deflators.27
We used the 2018 best available prices for commodities 
recommended by the testing and treatment guidelines 
(appendix p 10).9–11 For treatment, we assumed that all 
countries would optimise procurement and access 
medicines according to the prices already reported for 
high volume generic scenarios ($30 per year for HBV, 
using tenofovir;20 $105 per cure for HCV, using the 
pangenotypic sofosbuvir plus daclatasvir regimen).21,28
We quantified the human resources (ie, medical doctors 
and nurses) in terms of minutes (specific for each 
country) required for testing and treat ment irrespective of 
any integration with other services (appendix p 10). We 
multi plied this time by the number of tests and treatments 
initiated. We then checked that staffing needs fitted in the 
overall human resources requirements estimated in the 
SDG analysis.13
The method for programme costs followed that of the 
SDG investment scenario and considered management, 
training, monitoring, and evaluation. We considered that 
programme costs started in 2016 with 10% of the full 
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cost, and scaled up these amounts to 50% in 2030 for the 
progress scenario, and to 100% in 2030 for the ambitious 
scenario.
As for the broader SDG analysis, we calculated the 
incremental cost of each of the three scenarios using the 
2016 baseline cost as a reference.
Health effect
For the three scenarios, we modelled the health effect 
secondary to treatments initiated in 2016 on the basis of 
natural history and effectiveness of treatment.10,11 We 
used worldwide extensions of models for HBV29 and 
HCV,30 using background mortality estimated by the 
UN (appendix p 3). We expressed health benefit in terms 
of healthy life-years gained and deaths averted before 
and after 2030 for individuals with treatment initiated 
between 2016 and 2030 (ie, while individuals are alive). 
None of the health benefits were discounted.
Sensitivity analysis
We did three one-way sensitivity analyses for specific 
commodity costs. First, we assumed that the incidence 
of HCV infection did not decline as a result of 
prevention interventions. Second, we assumed that 
countries where direct acting antivirals for HCV were 
still protected by a patent in 2018 had to pay $5000 for a 
curative short-course treatment. Finally, we assumed 
that all countries would not have yet benefited from 
the price reduction of HCV RNA and HBV DNA 
amplification diagnostics and would pay $115 and 
$130 for each test, respectively.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The first and corresponding authors had full 
access to all the data and had final responsibility for the 
decision to submit for publication.
Results 
The 67 countries considered (2015 total population: 
5·6 billion people; appendix p 12) accounted for 230 mil-
lion people with HBV (90% of HBV infections world-
wide; appendix p 12) and 52 million people with HCV 
infection in 2015 (73% of HCV infections worldwide; 
appendix p 12).
The cumulative numbers of people tested for HBV 
infection were 93 million people for the flatline scenario, 
2400 million people for the progress scenario, and 
5502 million people for the ambitious scenario (appendix 
p 17). The num ber of people receiving HBV treatment 
in 2030 increased from 1·4 million (flatline scenario) to 
24·1 million people in the progress scenario and 32·2 mil -
lion people in the ambitious scenario (appendix p 19).
The cumulative numbers of people tested for HCV 
infection were 142 million people for the flatline scenario, 
850 million people for the progress scenario, and 
6129 million for the ambitious scenario (appendix p 18). 
The cumulative number of people placed on curative 
HCV treatment in 2030 increased from 10·5 million 
(flatline scenario) to 34·1 million (progress scenario) and 
61·6 million (ambitious scenario; appendix p 20).
The flatline scenario led to a total cost of $7·1 billion, 
with $5·5 billion (77%) used for HBV and $1·7 billion 
(23%) used for HCV (table 1). The progress scenario 
led to a total cost of $34·9 billion. Of this amount, 
$19·9 billion (57%) was for HBV, $5·9 billion (17%) for 
HCV, and $9·1 billion (26%) was for programme costs. 
The additional investment of the progress scenario 
over a continuation of the 2016 costs was $27·1 billion, 
accounting for 0·9% of the estimated cost presented by 
WHO for the SDG progress scenario. The ambitious 
scenario led to a total cost of $66·8 billion; $30·3 billion 
(45%) was for HBV, $16·0 billion (24%) was for HCV, and 
$20·5 billion (31%) was for programme costs. Adding 
hepatitis activities to the overall WHO SDG ambitious 
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Figure 1: Annual cost of testing and treatment for hepatitis B virus and hepatitis C virus, by scenario, in 
67 low-income and middle-income countries (2016–30)
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Figure 2: Costs according to the stage of care for hepatitis B virus testing and 
treatment, by scenario, in 67 low-income and middle-income countries 
(2016–30)
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scenario would require an additional $58·7 billion, 
accounting for a 1·5% increase in resource needs (table 1).
The requirements in terms of health-care worker time 
would be 7·5 million days for doctors and 9·4 million days 
for nurses (flatline scenario); 175·9 million days for 
doctors and 42·7 million days for nurses (progress 
scenario); and 432·3 million days for doctors and 
247·8 million days for nurses (ambitious scenario).13 
The cost of the flatline scenario slightly decreased over 
time, from $524·8 million to $474·5 million (figure 1). 
The annual cost of the progress scenario con sistently 
increased from 2016 ($524·7 million) to 2030 
($4·1 billion). The annual cost of the ambitious scenario 
increased until 2023 ($6·2 billion), decreased from 
2024 to 2027 ($5·6 billion), and then increased again 
until 2030 ($6·7 billion). The WHO Regions where the 
largest investment was needed was the western Pacific 
(table 1; appendix p 21), followed by Africa, South-East 
Asia, Eastern Mediterranean, Americas, and Europe.
For HBV, most costs were associated with initial diag-
nosis (serological test), treatment eligibility assess-
ment, and monitoring (figure 2). Diagnostics (HBsAg 
and HBV DNA tests) accounted for the majority of 
the costs (up to 69% in the ambitious scenario; 
appendix p 22). Medicines accounted only for a minority 
of the costs (up to 31% in the ambitious scenario). 
For HCV, the costs were spread between diagnosis, 
treatment asses sment, treatment, and monitoring 
(figure 3). Diag nostics (anti-HCV and HCV RNA) 
accounted for 58% and medicines for 42% of the costs 
in the ambitious scenario (appendix p 23).
Under the hypothesis that the incidence of HCV 
infection would not be reduced in the progress and 
ambitious scenarios, the cost of the ambitious scenario 
for HCV would increase from $16·0 billion to $17·4 bil-
lion (appendix p 14). The overall incremental cost 
of elimination would then reach $60·0 billion 
(appendix p 14).
In 2017, patents restricted access to generic direct acting 
antivirals for HCV in 13 countries. Under the hypothesis 
that they would have to continue to pay $5000 for a direct 
acting antiviral course, the cost of the ambitious sce-
nario for HCV would increase from $16·0 billion to 
$106·7 billion. The overall incremental cost of elimination 
would then reach $118·0 billion (appendix p 14).
In 2018, some countries still paid higher prices for HBV 
DNA testing ($130 instead of $20 reported in 2018 
with optimised procurement mechanisms).1 Under the 
hypothesis that such prices would be maintained for all 
countries, the total cost of the ambitious scenario for 
HBV would increase from $30·3 billion to $87·7 billion 
(appendix p 14).
Similarly, in 2018, some countries still paid high prices 
for HCV RNA testing ($115 instead of $20 reported in 2018 
with optimised procurement mechanisms).1 Assuming 
that these prices would be maintained for all countries, the 
total cost of the ambitious scenario for HCV would 
increase from $16·0 billion to $24·3 billion (appendix 
p 14). 
Implementation of the flatline scenario would have 
limited effect in terms of preventing mortality from 
HBV or HCV infection (table 2). In contrast, the progress 
scenario would avert 16·6 million premature deaths, 
3·0 million (18%) of which would be before 2030 (table 2). 
Of the deaths averted, 7·3 million (44%) were associated 
with HBV infection and 9·3 million (56%) were associated 
with HCV infection.
Treatment according to the progress scenario would 
also lead to a gain of 328·6 million healthy life-years, 
31·0 million (9%) of which would be before 2030 
(table 2). Further, the ambitious scenario would avert 
26·8 million premature deaths, 4·5 million (17%) of 
which would be before 2030. Of the deaths averted in 
this scenario, 9·7 million (36%) were associated with 
HBV infection and 17·1 million (64%) were associated 
with HCV infection.
Treatment according to the ambitious scenario would 
lead to a gain of 553·7 million healthy life-years, 
51·5 million (9%) of which would be before 2030 
(table 2). Adding hepatitis elimination to the ambitious 
SDG scenario would avert additionally more than 
97 million (4·6%) premature deaths13 and add more 
than 535·8 million (9·6%) healthy life-years13 from 
2016 to 2030.
Discussion
The estimated resource needs for testing and treatment 
for hepatitis from 2016 to 2030 (over the continuation of 
the 2016 baseline costs) ranged from $27 billion for the 
progress scenario to $58·7 billion for the ambitious 
elimination scenario. Under the ambitious elimination 
scenario, testing and treatment for HBV and HCV would 
account for a 1·5% increase in the previously published 
$3944 billion WHO SDG price tag. Cost estimates and 
the proportion of the price tag that they account for are 
Figure 3: Costs according to the stage of care for hepatitis C virus testing and 
treatment, by scenario, in 67 low-income and middle-income countries 
(2016–30)
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also available for other major infectious diseases, 
including HIV ($102 billion [2·5%]), tuberculosis 
($7 billion [1·4%]), and malaria ($51 billion [1·3%]), and 
are lower than for non-communicable diseases 
($421 billion [10·7%]). For this 1·5% increase in 
investment over the ambitious SDG scenario, by 2030, 
hepatitis elimination would avert an additional 
4·6% premature deaths and lead to the gain of an 
additional 9·6% healthy life-years. This scenario assumes 
that the health system will be successively strengthened 
to provide the infra structure and the human resources 
required for the delivery of these services, including 
prevention. The 2018 WHO investment case estimated 
that such an investment in health would have positive 
returns.31 Programme costs accounted for $20·5 billion, 
31% of the cost under the ambitious scenario. In some 
settings, some of these costs could be overestimated. 
According to the various situations, part of the costs 
could be reduced through efficiency savings from 
programme synergies or integrated approaches with 
compatible programmes or services, including HIV, 
tuberculosis, harm reduction, and correctional health.11
Although the price tag of an ambitious scenario for 
hepatitis testing and treatment represents around 
1% relative increase over the overall estimated cost for 
SDG health investments, affordability will be an issue in 
low-income countries. For hepatitis, financing solutions 
will be needed in low-income and middle-income countries 
where current financing schemes might not capture 
hepatitis testing and treatment.32 The Western Pacific and 
South-East Asia Regions are mostly constituted of middle-
income countries where revenue generation through 
economic growth could finance hepatitis within UHC. 
Furthermore, increasing health-care costs in these 
countries means that the cost of inaction in terms of 
chronic care for cirrhosis and hepatocellular carcinoma 
could be higher than the cost of paying for testing 
and treatment. Testing and treatment for HBV14 or 
HCV15 infection is indeed cost saving from a health-care 
perspective in many countries. In contrast, in the 
Africa Region, with few exceptions,33,34 the perspectives for 
domestic revenue generation for viral hepatitis elimi nation 
are less favourable. The limited use of health care for 
patients with cirrhosis and hepatocellular carcinoma 
nowadays means that HBV or HCV treatment is less likely 
to be cost saving from a health-care perspective. Thus, 
initial external funding through donor support could be 
crucial in getting testing and treatment initia tives scaled 
up beyond a small number of initiatives,35 particularly for 
HBV, which affects the Africa Region heavily.1 Finally, in a 
scenario of increased access to generic prices, middle-
income countries of the European and American Regions 
would require smaller disburse ments than other regions. 
Given the health-care cost for the management of sequelae, 
testing and treatment would probably be cost saving. 
However, this scenario requires additional price reductions 
of curative treatments for HCV in countries where direct 
acting antivirals are protected by patents.21
Scaling up HBV and HCV treatment is highly 
dependent on the availability and affordability of diag-
nostics and medicines. A large part of the costs is 
attributable to the testing because it would require 
testing a large number of people to identify 90% of 
those infected in settings of low prevalence. Our costing 
estimates were sensitive to the price of direct acting 
antivirals for HCV and HBV DNA tests. Sharp price 
reductions have taken place.21 In 2017, 62% of people 
infected with HCV lived in countries where they should 
be able to access a curative course of direct acting 
antiviral for $105. Newer direct acting antiviral regimens 
could be shorter, allowing for further price reduction.21 
However, in upper middle-income countries, where 
patents still protect direct acting antivirals, prices 
reported are around $3000–5000 for a course.21 Of the 
countries we considered, 13·1 million people living with 
HCV (25% of the total population with HCV in the 
67 countries) were in countries without access to 
generics. If these countries were to procure direct acting 
antivirals at $5000 per course, the ambitious price tag 
would be higher. For diagnostics, price reduc tion 
Deaths averted Healthy life-years gained Decompensated cirrhosis cases 
prevented
Hepatocellular carcinoma cases 
prevented
Flatline Progress Ambitious Flatline Progress Ambitious Flatline Progress Ambitious Flatline Progress Ambitious
HBV until 2030 198 289 2 380 607 3 361 518 1 551 122 16 470 601 23 924 254 93 327 1 271 834 1 750 731 109 219 1 442 776 2 006 580
HCV until 2030 286 433 608 713 1 147 167 6 698 067 14 509 316 27 550 471 152 783 307 875 604 880 353 129 804 178 1 525 136
Total until 2030 484 722 2 989 320 4 508 685 8 249 189 30 979 917 51 474 725 246 110 1 579 709 2 355 611 462 348 2 246 954 3 531 716
HBV after 2030 238 139 4 935 635 6 351 287 5 041 431 91 757 313 119 538 846 52 963 1 219 728 1 561 421 82 495 1 901 776 2 451 109
HCV after 2030 2 598 795 8 646 370 15 953 283 59 472 986 205 831 791 382 707 315 1 223 634 3 899 133 7 366 311 2 065 075 6 984 758 12 995 424
Total after 2030 2 836 934 13 582 005 22 304 570 64 514 418 297 589 104 502 246 161 1 276 597 5 118 861 8 927 732 2 147 570 8 886 534 15 446 533
HBV total 436 428 7 316 241 9 712 804 6 592 553 108 227 914 143 463 100 146 289 2 491 562 3 312 152 191 714 3 344 551 4 457 690 
HCV total 2 885 228 9 255 083 17 100 450 66 171 054 220 341 107 410 257 786 1 376 417 4 207 008 7 971 191 2 418 204 7 788 936 14 520 560
Total 3 321 656 16 571 324 26 813 254 72 763 606 328 569 020 553 720 886 1 522 706 6 698 570 11 283 343 2 609 918 11 133 487 18 978 250 
Table 2: Summary of the health effect of the flatline, progress, and ambitious scenarios of testing and treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in 
67 low-income and middle-income countries (2016–30 and longer than 2030 for treatments initiated between 2016–30)
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strategies (eg, open tenders, bulk procurement) would 
also have a large effect on feasibility.
Our cost estimates have several limitations. First, 
estimates are based on specific scenarios created 
to assimilate WHO recommendations algorithms, 
selected epidemiological parameters, and assumptions 
regarding the cost implications (quantities of resources 
needed and unit cost) in several countries. These 
estimates did not result from a full dynamic model 
simulating the joint effect of various interventions for 
prevention and treatment or to compare the effectiveness 
of various intervention scenarios with multidimensional 
sensitivity analyses. Second, our scenarios assume a 
strengthening of health systems and scaled up delivery 
of interventions that would prevent HBV and HCV 
infections but did not model prevention. The ambitious 
2015–30 costing to end the AIDS epidemic was based on 
the UNAID’s fast track scenario and included a service 
package for people who inject drugs (90% coverage) and 
opioid substitution therapy (40% coverage) designed to 
reduce needle (by 51%) and syringe sharing (by 71%),25,13 
noting that the target for needle and syringe distribution 
is higher for HCV than for HIV (300 vs 200 per user per 
year). If that package was not effective at reducing the 
incidence of HCV infection as we assumed,36 it would be 
unfortunate from a public health point of view but would 
not substantially affect the 2016–30 cost projections. 
Results of another sensitivity analysis that we did 
suggests that if incidence of HCV infection was not 
reduced, the cost of the ambitious scenario would 
increase from $66·8 billion to $68·2 billion. Third, 
scenarios are based on assumptions about the efficiency 
of testing, the probability of being tested twice, and the 
outcome of testing activities in terms of the proportion 
of people diagnosed with HBV and HCV infection. 
These assumptions are mostly theoretical at this stage 
given the limited real-world experience of programmes 
to test people from the general population.37–39 Our 
projections led to a large number of people who needed 
to be tested for a 2015 baseline population of 5·6 billion. 
For HBV, our projections for elimination call for testing 
5·5 billion people (0·98 tests per 2015 population). As a 
reference, a global HBV model called for testing every 
person once in populations in low prevalence areas.3 For 
HCV, our projections for elimination call for testing 
6·1 billion people (1·1 tests per 2015 population). As a 
reference, a similar type of analysis done in Malaysia 
called for testing a total of 6 million people for an 
adult population of 18 million to reach elimination.40 A 
global investment case estimated that reaching HCV 
elimination would require testing 70% of the global 
adult population.35 More experiences are needed so that 
we can better quantify the outcome of such programmes. 
Fourth, our analysis did not take into account the savings 
to the health sector because of prevented decompensated 
cirrhosis and hepatocellular carcinoma. These savings 
were estimated in the cost-effectiveness analyses that 
are complementary to our cost projections.41,42 In high-
burden settings, elimination would lead to a positive 
return on investment.43,44 Finally, our cost projections are 
based on the assumption that 25% of people with 
HBV infection would be eligible for treatment. WHO-
endorsed global estimates of the proportion of HBsAg-
positive people who are eligible for treatment are not 
available. Published studies in selected countries suggest 
that the proportion of eligibility ranges from under 
5% in community-based studies in Africa37 to around 
25% in health-care facility-based studies.45,46 A higher or 
lower proportion of people eligible for treatment would 
decrease or increase the effect of testing and treatment 
programmes, respectively.
In conclusion, the estimation of the price tag for 
testing and treatment of HBV and HCV infection points 
to three main conclusions. First, additional resources 
needed for testing and treatment of HBV and HCV 
infection within a broader UHC ambitious scenario 
represents an additional 0·9% and 1·5% of UHC price 
tag for the progress and ambitious scenarios, respec-
tively. Second, the Western Pacific and African Regions 
need to invest the most, given population sizes and 
prevalence of HBV infection. Third, the price of HBV 
DNA tests and HCV direct acting antivirals are the 
main cost drivers. These conclusions point to several 
recommendations. First, WHO member states should 
consider that hepatitis testing and treatment is a high-
impact intervention that deserves to be funded as part 
of UHC. Integrated service delivery models11 would 
improve programme efficiency. Second, WHO member 
states should consider optimising procurement of 
affordable medicines effective against HBV and HCV 
infection along with WHO flowcharts.21 For tenofovir 
and for countries where direct acting antivirals are not 
protected by a patent, countries need to register products 
from multiple generic manufacturers to encourage 
competition with tenders. In countries where direct 
acting antivirals are protected by a patent, national 
programmes need to negotiate price and volume with 
originators until the price reached is compatible with 
national scaled up implementation.21 Third, appropriate 
forecasting, open tenders, and bulk procurement for 
price–volume reduc tions should take place so that the 
price of diag nostics tests can decrease. If the price of 
nucleic acid tests, such as HBV DNA and HCV RNA, 
were to decrease to less than $5 per test—a price men-
tioned as a possible target in the field of diagnostics47—
elimination could be greatly facilitated. Implementation 
science could also identify better service delivery 
models and alternative, more cost-effective ways to 
monitor the effectiveness of treatment in people treated 
for HBV infection through, for example, the use of liver 
function tests instead of HBV DNA. Implementation 
of these recommendations provide a feasible way 
forward to reach elimination of hepatitis in the context 
of UHC.
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